BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/10/2024 9:27:23 AM | Browse: 269 | Download: 684
 |
Received |
|
2024-05-26 09:48 |
|
Peer-Review Started |
|
2024-05-26 09:49 |
|
First Decision by Editorial Office Director |
|
2024-08-10 06:22 |
|
Return for Revision |
|
2024-08-10 06:22 |
|
Revised |
|
2024-08-19 17:20 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-08-27 02:40 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-08-27 06:15 |
|
Articles in Press |
|
2024-08-27 06:15 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-09-03 07:51 |
|
Publish the Manuscript Online |
|
2024-09-10 09:27 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Biochemistry & Molecular Biology |
| Manuscript Type |
Editorial |
| Article Title |
Glucagon-like peptide 1 receptor agonist: A potential game changer for cholangiocarcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ronnakrit Trakoonsenathong, Ching-Feng Chiu and Charupong Saengboonmee |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Mekong - Lancang Cooperation Special Fund |
|
| Cho-Kalaphruek Excellent Research Project for Medical Students |
|
| The International Internship Pilot Program |
IIPP2023283 |
|
| Corresponding Author |
Charupong Saengboonmee, MD, PhD, Assistant Professor, Department of Biochemistry, Faculty of Medicine, Khon Kaen University, 123 Mittraphap Highway, Khon Kaen 40002, Thailand. charusa@kku.ac.th |
| Key Words |
Carcinogenesis; Cholangiocarcinoma; Diabetes mellitus; Incretin; Glucagon-like peptide 1 receptor |
| Core Tip |
Glucagon-like peptide 1 receptor (GLP-1R) agonists, an anti-diabetic drug with other systemic benefits, have been reported for their association with increased risk of some cancers. Although the associations between GLP-1R agonists and the risk of cholangiocarcinoma (CCA) have not been consensus, the use of GLP-1R agonists showed the anti-tumor effects against CCA in vitro and animal models are evident. This editorial reviews and discusses recent studies of the effects of GLP-1R agonists both at epidemiological and molecular levels. The understanding of how GLP-1R agonist affects CCA will be beneficial for the management of patients with CCA and diabetes mellitus. |
| Publish Date |
2024-09-10 09:27 |
| Citation |
Trakoonsenathong R, Chiu CF, Saengboonmee C. Glucagon-like peptide 1 receptor agonist: A potential game changer for cholangiocarcinoma. World J Gastroenterol 2024; 30(34): 3862-3867 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i34/3862.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i34.3862 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
